贝利尤单抗对狼疮肾炎肾脏结局与肾功能保护的事后分析
BLISS-LN 是一项 3 期、多国、双盲、104 周试验,448 例狼疮肾炎患者随机接受静脉贝利尤单抗 10 mg/kg 或安慰剂联合标准治疗。事后分析显示,贝利尤单抗加用可降低肾脏相关事件或死亡及狼疮肾炎复发风险,并降低 eGFR 持续下降风险、减缓 eGFR 年下降速率。
要点
- 贝利尤单抗加用标准治疗可降低狼疮肾炎患者肾脏相关事件或死亡及复发风险。
- 贝利尤单抗可降低 eGFR 持续下降 30% 或 40% 的风险并减缓 eGFR 年下降速率。
- 对增殖性狼疮肾炎且基线尿蛋白/肌酐比值低于 3 g/g 者,贝利尤单抗改善肾脏缓解更明显。
核心结论
- 在标准治疗基础上加用贝利尤单抗可降低狼疮肾炎患者复发及 eGFR 下降风险。
研究设计与样本
- BLISS-LN 为 3 期、多国、双盲、104 周试验,448 例狼疮肾炎患者随机接受静脉贝利尤单抗 10 mg/kg 或安慰剂联合标准治疗。
- 标准治疗为环磷酰胺/硫唑嘌呤或吗替麦考酚酯。
- 本文为 BLISS-LN 的事后分析。
主要发现
- 贝利尤单抗加用对增殖性狼疮肾炎且基线尿蛋白/肌酐比值低于 3 g/g 的患者改善主要疗效肾脏应答和完全肾脏应答最有效。
- 对存在上皮下沉积或基线尿蛋白/肌酐比值≥3 g/g 的狼疮肾炎患者,贝利尤单抗未观察到肾脏应答改善。
- 贝利尤单抗显著降低总体人群肾脏相关事件或死亡及狼疮肾炎复发风险。
- 贝利尤单抗较单用标准治疗降低 eGFR 持续下降 30% 或 40% 的风险,并减缓仍在研究中的患者的 eGFR 年下降速率。
临床怎么用
- 对增殖性狼疮肾炎且基线尿蛋白/肌酐比值低于 3 g/g 的患者,可考虑标准治疗加用贝利尤单抗以改善肾脏应答。
- 贝利尤单抗加用标准治疗可用于降低狼疮肾炎复发及 eGFR 下降风险。
局限性
- 本文为 BLISS-LN 的事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We performed a post hoc analysis of the Belimumab International Study in Lupus Nephritis (BLISS-LN), a Phase 3, multinational, double-blind, 104-week trial, in which 448 patients with lupus nephritis were randomized to receive intravenous belimumab 10 mg/kg or placebo with standard therapy (cyclophosphamide/azathioprine or mycophenolate mofetil). Add-on belimumab was found to be most effective in improving the primary efficacy kidney response and complete kidney response in patients with proliferative lupus nephritis and a baseline urine protein/creatinine ratio under 3 g/g. However, there was no observed improvement in the kidney response with belimumab treatment in patients with lupus nephritis and sub-epithelial deposits or with a baseline protein/creatinine ratio of 3 g/g or more. Belimumab significantly reduced the risk of kidney-related events or death and lupus nephritis flare in the overall population. Belimumab reduced the risk of a sustained 30% or 40% decline in estimated glomerular filtration rate (eGFR) versus standard treatment alone and attenuated the annual rate of eGFR decline in patients who remained on-study. Thus, our data suggest that the addition of belimumab to standard therapy could attenuate the risk of lupus nephritis flare and eGFR decline in a broad spectrum of patients with lupus nephritis.
引用
- Rovin BH, Furie R, Teng YKO, et al. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int. 2021. PMID: 34560137. doi:10.1016/j.kint.2021.08.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。